GS Paper III · IPR · Public Health · Pharmaceutical Sector
🔄 Evergreening of Patents — Profits Over People?
What is Evergreening · How It Works · India's Defence (Section 3d) · Novartis Glivec Case 2013 · Bedaquiline TB Drug · Lenacapavir HIV Drug 2024 · Compulsory Licensing · Doha Declaration · India's Role as Global Pharmacy · PYQs & MCQs
🔄
What is Evergreening of Patents? — The "Eternal Monopoly" Trick
Definition · Patent Lifecycle · Why Companies Do It
📖 Definition
Evergreening is a corporate strategy used by pharmaceutical (and other) companies to extend their patent monopoly beyond the standard 20-year patent term by filing new patents on minor modifications of an existing drug — such as new salt forms, new dosages, new delivery methods, new combinations, or new formulations — without any significant improvement in therapeutic effectiveness. Also called "secondary patenting."
🧠 Simple Analogy — For Non-Science Students
Imagine you own the only bakery that makes a special bread. The recipe is protected for 20 years — no one else can bake it. Just before your protection expires, you change the bread's shape from round to square — same ingredients, same taste, same nutrition — and apply for a fresh 20-year patent on the "new square bread." That's evergreening. The customer (patient) still pays monopoly prices. Generic bakers (pharmaceutical companies) remain shut out. The "innovation" is trivial — just a shape change.
⏱ The Patent Lifecycle — How Evergreening Disrupts It
Without Evergreening (Normal) vs With Evergreening
✅ NORMAL Patent Lifecycle
Year 0
Patent Filed
Research &
Trials Begin
Research &
Trials Begin
→
Year 5–8
Drug Approved
Market Launch
Monopoly Profits
Market Launch
Monopoly Profits
→
Year 20
Patent Expires
Generic Entry
Prices Drop 80%
Generic Entry
Prices Drop 80%
→
Year 20+
Affordable
Generic Drugs
Public Access ✅
Generic Drugs
Public Access ✅
❌ With Evergreening
Year 0
Original Drug
Patent Filed
Patent Filed
→
Year 15–18
Minor Tweak:
New Salt Form
Patent Filed
New Salt Form
Patent Filed
→
Year 20
Original Patent
Expires BUT
New Patent Active
Expires BUT
New Patent Active
→
Year 35–40
Monopoly
Continues ❌
No Generics!
Continues ❌
No Generics!
Access to affordable medicines is a fundamental right. When drug patents expire, generic manufacturers can produce the same medication at 80–90% lower prices. Evergreening artificially delays this price drop by extending monopoly beyond the 20-year patent term. (Source: Wikimedia Commons)
💊 Why Companies Evergreen
When a patent expires, the drug price drops by 80–90% due to generic competition. For a blockbuster drug generating $1 billion annually, even 2 extra years of monopoly = $2 billion in additional revenue.
Methods used:
• New salt / polymorph forms of the same drug
• New dosage (100mg → 150mg)
• New delivery system (tablet → capsule)
• New combination with another known drug
• New treatment schedule / slow release formulation
• Filing a patent on metabolites (breakdown products)
• New indication for an existing approved drug
Methods used:
• New salt / polymorph forms of the same drug
• New dosage (100mg → 150mg)
• New delivery system (tablet → capsule)
• New combination with another known drug
• New treatment schedule / slow release formulation
• Filing a patent on metabolites (breakdown products)
• New indication for an existing approved drug
🇮🇳 India's Stake — "Pharmacy of the World"
India supplies 20% of global generic medicines by volume and provides 60% of WHO's vaccines. India's pharma sector is valued at $50+ billion and serves 200+ countries. India's generic drugs have been called the "lifeline" of developing countries' healthcare — treating HIV/AIDS in Africa, TB globally, and cancer worldwide. If evergreening succeeds in India, generic production is blocked → prices stay prohibitively high → millions die of preventable diseases. India's resistance to evergreening is NOT just a domestic IP policy — it is a global public health issue.
🇮🇳
India's Legal Defence Against Evergreening High Yield
Section 3(d) · Section 3(e) · Section 3(i) · Pre-Grant Opposition · Compulsory Licensing
⚖ Section 3(d) of the Indian Patents Act 1970 — The Anti-Evergreening Weapon Most Tested
Verbatim (simplified): "The mere discovery of a new form of a known substance which does NOT result in the enhancement of the known efficacy of that substance" is NOT patentable.
Key word: EFFICACY — not just bioavailability, not just convenience, not just commercial novelty. The new form must show significantly enhanced therapeutic efficacy — i.e., it must actually work better as a medicine.
What it blocks: Patents for new salts, esters, ethers, polymorphs, pure forms, metabolites, new dosages, new delivery systems of known drugs — UNLESS they show genuinely improved therapeutic efficacy.
Key word: EFFICACY — not just bioavailability, not just convenience, not just commercial novelty. The new form must show significantly enhanced therapeutic efficacy — i.e., it must actually work better as a medicine.
What it blocks: Patents for new salts, esters, ethers, polymorphs, pure forms, metabolites, new dosages, new delivery systems of known drugs — UNLESS they show genuinely improved therapeutic efficacy.
Context: Added through the 2005 amendment to the Patents Act (required for India to comply with TRIPS, joining WTO in 1995). India used this to ensure TRIPS compliance did NOT open the door to evergreening.
Landmark validation: Supreme Court upheld Section 3(d) in Novartis AG v. Union of India (2013) — rejecting Glivec's patent. Called a landmark victory for global public health.
Landmark validation: Supreme Court upheld Section 3(d) in Novartis AG v. Union of India (2013) — rejecting Glivec's patent. Called a landmark victory for global public health.
WIPO recognition: WIPO has publicly cited India's Section 3(d) as a model approach for preventing evergreening while complying with TRIPS. Several countries have studied India's framework for adoption.
🛡 India's Complete Anti-Evergreening Arsenal
| Provision | What It Says | Impact on Evergreening |
|---|---|---|
| Section 3(d) Main Shield |
New forms of known substances (salts, polymorphs, dosages, metabolites) are not patentable UNLESS they show significantly enhanced therapeutic efficacy | Directly blocks the most common evergreening strategy — filing patents on salt forms, new dosages, and new formulations of existing drugs without genuine innovation |
| Section 3(e) | Mixtures of known compounds are not patentable unless there is a synergistic effect | Prevents companies from patenting new combinations of two known drugs (which already have established efficacy) just to extend market exclusivity |
| Section 3(i) | Methods of treatment of human or animal disease, or diagnostic methods, are NOT patentable | Prevents companies from claiming exclusivity over treatment protocols or methods using known drugs — a backdoor to extending monopoly through method patents |
| Section 84 (Compulsory Licensing) | Government can grant licence to a generic company to produce a patented drug if it is not available at reasonably affordable price, or not manufactured in India, or not meeting reasonable requirements of the public | Even if evergreening partially succeeds and a patent is granted, CL allows generic production if the drug is unaffordable. Natco-Bayer 2012 = India's first CL. Nexavar cancer drug price: ₹2.8 lakh → ₹8,880 |
| Pre-Grant Opposition (Section 25(1)) | Any person can oppose a patent application BEFORE it is granted, citing prior art, lack of novelty, or Section 3(d) grounds | Civil society groups, patient organisations, generic manufacturers can challenge evergreening patent applications BEFORE they are granted — preventing the problem at source |
| Post-Grant Opposition (Section 25(2)) | Any person can challenge a granted patent within 12 months of grant on similar grounds | Allows challenges even after a patent is mistakenly granted, providing a second line of defence against evergreening |
| Section 107A (Bolar Provision) | Allows generic manufacturers to use patented drugs for regulatory approval submissions without infringement, even before patent expiry | Ensures generic drugs can be ready for market launch the moment a patent expires — preventing delays that would effectively extend exclusivity beyond the patent term |
🧠 Remember: India vs USA on Evergreening
India: Section 3(d) bars evergreening. New forms need EFFICACY proof. Strong generic industry protection. Compulsory licensing allowed.
USA (Hatch-Waxman Act): Allows 5-year patent extension for regulatory delays. 30-month stay provisions. More conducive to secondary patents. Stronger evergreening occurs.
Result: Same cancer drug — Glivec — was available in India for ₹8,000/month (Natco generic) vs ₹1.2 lakh/month (Novartis original). Section 3(d) saved millions of Indian lives.
USA (Hatch-Waxman Act): Allows 5-year patent extension for regulatory delays. 30-month stay provisions. More conducive to secondary patents. Stronger evergreening occurs.
Result: Same cancer drug — Glivec — was available in India for ₹8,000/month (Natco generic) vs ₹1.2 lakh/month (Novartis original). Section 3(d) saved millions of Indian lives.
⚖
Key Cases — India's Victories Against Evergreening
Novartis · Cipla-Roche · Bedaquiline · Lenacapavir 2024
⚖
Novartis AG v. Union of India (2013) — Supreme Court of India
The Glivec / Gleevec Case · Landmark Global Public Health Verdict Most Important
Drug: Imatinib mesylate (brand name Glivec/Gleevec) — a targeted therapy for Chronic Myeloid Leukaemia (CML), a blood cancer.
What Novartis claimed: The beta-crystalline form of imatinib mesylate was a new patentable invention — different from the known free-base form of imatinib that had been published earlier (and whose patent had already expired in many countries).
India's position: The Controller General of Patents rejected Novartis's application under Section 3(d) — because imatinib mesylate (a salt form) was a new form of the KNOWN substance imatinib, and Novartis could not demonstrate significantly enhanced therapeutic efficacy (the SC noted that merely showing 30% better bioavailability is NOT the same as showing better therapeutic efficacy).
What Novartis claimed: The beta-crystalline form of imatinib mesylate was a new patentable invention — different from the known free-base form of imatinib that had been published earlier (and whose patent had already expired in many countries).
India's position: The Controller General of Patents rejected Novartis's application under Section 3(d) — because imatinib mesylate (a salt form) was a new form of the KNOWN substance imatinib, and Novartis could not demonstrate significantly enhanced therapeutic efficacy (the SC noted that merely showing 30% better bioavailability is NOT the same as showing better therapeutic efficacy).
SC Verdict (April 2013): A two-judge bench of the Supreme Court dismissed Novartis's appeal by 2-0. The Court held: the beta-crystalline form of imatinib mesylate failed to satisfy Section 3(d) because it did not show "significantly enhanced efficacy." The mere improvement in bioavailability was NOT enough — actual therapeutic benefit was needed.
Impact: Glivec's price: Novartis ₹1.2 lakh/month → Natco generic ₹8,000/month. Natco then supplied it FREE to 16,000 patients in India.
Impact: Glivec's price: Novartis ₹1.2 lakh/month → Natco generic ₹8,000/month. Natco then supplied it FREE to 16,000 patients in India.
Global significance: MSF (Médecins Sans Frontières/Doctors Without Borders) called it a "victory for patients in India and around the world." The verdict was front-page news in every major global newspaper. It confirmed India's legal right to maintain Section 3(d) despite TRIPS obligations.
⚖
Cipla v. Roche (Delhi High Court, 2012) — Erlotinib Cancer Drug
Anti-Cancer Drug · Court Upheld Generic Production · Public Health Priority
Drug: Erlotinib (brand: Tarceva) — targeted therapy for non-small cell lung cancer.
What happened: Roche held a patent on erlotinib. Cipla produced a generic version at ₹1,600/month vs Roche's ₹4,500/month. Roche sued for patent infringement. Cipla argued the erlotinib patent itself was vulnerable to Section 3(d) challenge.
Delhi HC verdict: The Court refused to grant an injunction against Cipla, noting that a cancer drug at ₹4,500/month was unaffordable to most Indian patients while the generic was accessible. The court explicitly balanced patent rights against public health — a landmark judicial recognition of the "access to medicines" principle in Indian courts.
Significance: First significant Indian case where a court explicitly considered the "right to health" and affordability when deciding on patent injunctions. Set precedent that Indian courts will weigh public health against private IP rights.
What happened: Roche held a patent on erlotinib. Cipla produced a generic version at ₹1,600/month vs Roche's ₹4,500/month. Roche sued for patent infringement. Cipla argued the erlotinib patent itself was vulnerable to Section 3(d) challenge.
Delhi HC verdict: The Court refused to grant an injunction against Cipla, noting that a cancer drug at ₹4,500/month was unaffordable to most Indian patients while the generic was accessible. The court explicitly balanced patent rights against public health — a landmark judicial recognition of the "access to medicines" principle in Indian courts.
Significance: First significant Indian case where a court explicitly considered the "right to health" and affordability when deciding on patent injunctions. Set precedent that Indian courts will weigh public health against private IP rights.
🫁
Johnson & Johnson — Bedaquiline TB Drug (India, 2023)
MDR-Tuberculosis Drug · Patent Extension Rejected · Generic Access Secured
Drug: Bedaquiline — a critical drug for treating Multi-Drug Resistant TB (MDR-TB), where first-line drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) have failed. Oral drug with fewer side effects than injectable alternatives. High success rate in treating MDR-TB.
What J&J attempted: Filed patent applications seeking to extend its monopoly on bedaquiline in India beyond July 2023, when the original patents were expiring.
India's response: The Indian Patent Office rejected J&J's plea for patent extension — a clear application of anti-evergreening provisions. The secondary patent claims did not meet the thresholds required under India's patent law.
What J&J attempted: Filed patent applications seeking to extend its monopoly on bedaquiline in India beyond July 2023, when the original patents were expiring.
India's response: The Indian Patent Office rejected J&J's plea for patent extension — a clear application of anti-evergreening provisions. The secondary patent claims did not meet the thresholds required under India's patent law.
Impact: After patent expiry, Indian generic manufacturers (including Lupin and Macleods) could now produce bedaquiline. The drug cost was ~$400 for a full 6-month treatment course. Generic production is expected to reduce this significantly, making MDR-TB treatment accessible to millions globally.
Global impact: MDR-TB affects ~500,000 people annually worldwide. India has the highest MDR-TB burden. Generic bedaquiline from India will save countless lives.
Global impact: MDR-TB affects ~500,000 people annually worldwide. India has the highest MDR-TB burden. Generic bedaquiline from India will save countless lives.
UPSC angle: This case is a model example of how India's patent regime protects public health while complying with international IP obligations. Links to India's role as "pharmacy of the world" and Global South leadership in access to medicines.
💉 Gilead Sciences — Lenacapavir HIV Drug (India, 2024) Latest Current Affairs
Drug: Lenacapavir (brand: Sunlenca) — a long-acting HIV prevention/treatment drug by Gilead Sciences (USA). Administered as twice-yearly injections (every 6 months). Clinical trials showed 100% efficacy in women in sub-Saharan Africa and 99.9% in another trial. UNAIDS called it a potential "game-changer" in ending AIDS.
Cost problem: At ~$42,250 per patient per year (US price), this drug is completely inaccessible to patients in India and most of the developing world. India had 25.61 lakh people living with HIV in 2024 and 64,470 new infections.
What Gilead attempted: Filed patents in India for the choline and sodium salt forms of lenacapavir — if granted, these patents would extend Gilead's monopoly in India until 2038.
Cost problem: At ~$42,250 per patient per year (US price), this drug is completely inaccessible to patients in India and most of the developing world. India had 25.61 lakh people living with HIV in 2024 and 64,470 new infections.
What Gilead attempted: Filed patents in India for the choline and sodium salt forms of lenacapavir — if granted, these patents would extend Gilead's monopoly in India until 2038.
Opposition — Sankalp Rehabilitation Trust: Filed Pre-Grant Oppositions (PGOs) in India's Patent Office. Argued: salt forms of lenacapavir are known forms of a previously known compound → do not qualify under Section 3(d) → should not be patentable.
September 2024: Indian Patent Office scheduled hearings on these objections.
October 2024: Gilead signed voluntary licensing agreements with 6 generic manufacturers for 120 low-and-middle-income countries (including India) — offering royalty-free licences. This was seen as a response to patent opposition pressure.
September 2024: Indian Patent Office scheduled hearings on these objections.
October 2024: Gilead signed voluntary licensing agreements with 6 generic manufacturers for 120 low-and-middle-income countries (including India) — offering royalty-free licences. This was seen as a response to patent opposition pressure.
Argentina 2025: Argentina rejected Gilead's similar patent application — potentially allowing generic entry. Activists hope India's Patent Office decision (pending) will set a similar global precedent. Generic manufacturing cost estimated at just $25–40/year — vs $42,250 originator price.
💊
Tackling Evergreening — Solutions & Way Forward
Doha Declaration · CL · TRIPS Waivers · Voluntary Licensing · Policy
📋
Section 3(d) — India's Model
India's Section 3(d) is the gold standard for anti-evergreening legislation globally. Countries like Argentina and Brazil have adopted similar provisions. WIPO has recognised it as a model approach. Other developing countries should adopt similar efficacy thresholds in patent law.
⚖
Compulsory Licensing (Section 84)
Even when patents are granted, CL allows generic production for public health. India's Natco-Bayer 2012 case showed CL's effectiveness. TRIPS Article 31 and Doha Declaration 2001 support CL for public health. Needs to be more proactively used.
🌍
Doha Declaration 2001
WTO Doha Declaration confirmed that TRIPS should not prevent member countries from "taking measures to protect public health." Explicitly endorsed the right to use CL and determine what constitutes a national health emergency. India-South Africa joint leadership on this.
🤝
Voluntary Licensing
Patent holders proactively licence to generic manufacturers at low/no royalty for certain countries — like Gilead's Oct 2024 VL for lenacapavir in 120 LMICs. Better than CL (no litigation) but depends on corporate goodwill. Critics: restrictive conditions can limit competition.
🔬
Pre/Post-Grant Opposition
India's system allows civil society, patients, and generic companies to challenge evergreening patents BEFORE and AFTER granting. Lenacapavir case shows civil society's vital role. More countries need robust opposition mechanisms in their patent systems.
📊
TRIPS Amendment & WTO Reform
India and South Africa's 2020 proposal for TRIPS waiver for COVID-19 vaccines/therapeutics gained global attention. India should continue pushing at WTO to amend TRIPS to mandate disclosure of traditional knowledge origin and strengthen public health safeguards.
📌 Why Developed Countries Must Change — The Moral Argument
The TRIPS Agreement was designed to incentivise innovation by granting monopoly rights. But it was NOT designed to grant perpetual monopolies through evergreening. The "patent bargain" — public disclosure of invention in exchange for limited monopoly — breaks down when companies use minor tweaks to extend exclusivity indefinitely. The right to protect public health — particularly universal access to medicines — must take precedence over the protection of intellectual property. Every developing country that loses a drug to evergreening doesn't just face an economic problem — it faces preventable deaths. India's legal framework is a model the world should follow.
📜
PYQs & Practice MCQs
UPSC Prelims & Mains · Section 3d · Novartis · Compulsory Licensing
📜 UPSC Prelims Pattern — Section 3(d) & Evergreening Repeat Probability High
Pattern Q
Q. With reference to Section 3(d) of India's Patents Act 1970, consider the following statements:
- It prohibits patents on new forms of known substances if they do not show significantly enhanced therapeutic efficacy.
- The Supreme Court in Novartis AG v. Union of India (2013) held that this section violates India's TRIPS obligations under the WTO agreement.
- This provision was introduced through the 2005 amendment to the Patents Act to comply with TRIPS while protecting public health.
- a) 2 and 3 only
- b) 1 and 3 only ✓
- c) 1, 2 and 3
- d) 1 only
Statement 1 CORRECT: Section 3(d) prohibits patents on new forms of known substances (new salts, polymorphs, dosages, metabolites, etc.) UNLESS they show significantly enhanced therapeutic efficacy compared to the known substance. This is the core anti-evergreening provision.
Statement 2 WRONG: The Supreme Court (Novartis v. India, 2013) did the OPPOSITE — it UPHELD Section 3(d) and dismissed Novartis's argument that the provision violated TRIPS. The SC ruled that TRIPS Article 27 requires inventive step, and trivial modifications without efficacy improvement do NOT meet this threshold. Section 3(d) is therefore TRIPS-compliant.
Statement 3 CORRECT: Section 3(d) was inserted through the Patents (Amendment) Act 2005, when India amended its patent law to comply with TRIPS (joining WTO in 1995, transition period used until 2005). India crafted Section 3(d) specifically to comply with TRIPS while preventing evergreening — a careful balance between international obligations and domestic public health priorities.
Statement 2 WRONG: The Supreme Court (Novartis v. India, 2013) did the OPPOSITE — it UPHELD Section 3(d) and dismissed Novartis's argument that the provision violated TRIPS. The SC ruled that TRIPS Article 27 requires inventive step, and trivial modifications without efficacy improvement do NOT meet this threshold. Section 3(d) is therefore TRIPS-compliant.
Statement 3 CORRECT: Section 3(d) was inserted through the Patents (Amendment) Act 2005, when India amended its patent law to comply with TRIPS (joining WTO in 1995, transition period used until 2005). India crafted Section 3(d) specifically to comply with TRIPS while preventing evergreening — a careful balance between international obligations and domestic public health priorities.
📜 UPSC Mains 2019 — GS Paper III (15 marks)
Mains Pattern
Q. "The concept of evergreening of patents in the pharmaceutical sector has serious implications for public health, particularly in developing countries." Critically examine. (15 marks)
Model Answer Framework:
Model Answer Framework:
- Introduction: Define evergreening — strategy of filing secondary patents on minor modifications of existing drugs to extend monopoly beyond 20 years. "Profits over people" critique. India = pharmacy of the world (20% of global generics).
- How it works: Patent expiry → generic entry → 80% price drop (example: Glivec ₹1.2 lakh → ₹8,000 after generic entry). Companies file for new salt/dosage/combination patents to prevent this. Methods: new salt forms, new polymorphs, new release mechanisms, new combinations, metabolites.
- Public health implications: Cancer drugs, HIV drugs, TB drugs unaffordable → preventable deaths. MDR-TB: bedaquiline $400/6 months; lenacapavir $42,250/year for HIV prevention. Developing countries bear the burden while developed world companies profit.
- India's legal defence: Section 3(d) — new forms need enhanced EFFICACY proof. Section 3(e) — mixtures need synergistic effect. Section 84 — Compulsory Licensing. Section 25 — Pre/Post-Grant Opposition. Novartis 2013 SC vindication.
- Key cases: Novartis-Glivec (2013, SC upheld Section 3d) · Cipla-Roche erlotinib (2012, Delhi HC balanced IP vs public health) · J&J-Bedaquiline (2023, Patent Office rejected extension) · Gilead-Lenacapavir (2024, Pre-Grant Opposition hearings ongoing)
- International dimension: TRIPS Article 31 CL provision. Doha Declaration 2001 (India co-led). India-South Africa TRIPS Waiver Proposal 2020 (COVID). WIPO recognition of India's Section 3(d) as model.
- Criticism of India's approach: Discourages FDI in pharma R&D. Companies argue they need revenue from existing drugs to fund new ones. Risk of generic quality issues. Needs stronger post-market surveillance.
- Way forward: Global adoption of Section 3(d) type provisions. Strengthened use of CL. More transparent patent office processes. TRIPS reform at WTO. Differential pricing for LMICs. Publicly funded R&D for neglected diseases.
🧪 Practice MCQs — Evergreening (Click to attempt)
Q1. The Indian Patent Office's rejection of Johnson & Johnson's attempt to extend its monopoly on Bedaquiline (a tuberculosis drug) beyond July 2023 is significant because:
- (a) It marked the first-ever case of compulsory licensing in India for a TB drug
- (b) It allowed J&J to retain its patent for another 10 years under international trade law obligations
- (c) It prevented the evergreening of a critical MDR-TB drug, allowing generic manufacturers like Lupin and Macleods to produce affordable versions, making treatment accessible to millions globally
- (d) It established that all TB drugs in India are exempt from patent protection under the Indian Constitution
The Bedaquiline case is a landmark in India's anti-evergreening jurisprudence. J&J's original patents on bedaquiline were expiring in July 2023. By rejecting J&J's attempts to obtain secondary patents (which would have extended exclusivity), the Indian Patent Office applied India's anti-evergreening provisions to ensure that upon patent expiry, generic manufacturers could legally produce bedaquiline. This was NOT a compulsory licence (option a) — compulsory licensing happens while a patent is still in force. The Bedaquiline case simply ensured natural patent expiry was not artificially extended. Generic bedaquiline is critical because MDR-TB (Multi-Drug Resistant Tuberculosis) kills hundreds of thousands annually, and the $400 course cost (at originator prices) is unaffordable for most patients in India and other developing countries. Indian generic production dramatically reduces this cost.
Q2. In the Novartis AG v. Union of India (2013) Supreme Court case, the Court rejected Novartis's patent for Glivec (imatinib mesylate) because:
- (a) The drug was not manufactured in India, making it ineligible for Indian patent protection
- (b) The beta-crystalline form of imatinib mesylate, while showing improved bioavailability (30%), did not demonstrate significantly enhanced therapeutic efficacy over the known free-base form of imatinib, failing the test of Section 3(d)
- (c) Novartis had filed a patent for the same drug in the USA, making it ineligible for an Indian patent under bilateral trade agreements
- (d) Imatinib was a mixture of known compounds without synergistic effect, making it unpatentable under Section 3(e)
The Novartis case turned specifically on the distinction between bioavailability and therapeutic efficacy under Section 3(d). Novartis argued that the beta-crystalline form of imatinib mesylate (the salt form) showed 30% better bioavailability than the free-base form — and that this improvement justified a new patent. The Supreme Court rejected this argument. The Court held that Section 3(d) requires demonstration of enhanced therapeutic efficacy — i.e., the drug must actually work better in treating disease. Improved bioavailability (how well the body absorbs the drug) is not the same as improved therapeutic efficacy (how much better the drug treats the condition). Since Novartis could only show bioavailability improvement, not therapeutic improvement, the patent was rightly rejected. Imatinib (the free-base form) had been a known substance — imatinib mesylate was just a new form, and a new form without enhanced therapeutic efficacy is not patentable under Section 3(d).
Q3. India's first Compulsory Licence (CL) was granted in 2012 for which drug, and what was the price impact?
- (a) Sorafenib (Nexavar) — Bayer's cancer drug. Price fell from ₹2.8 lakh/month (Bayer) to ₹8,880/month (Natco), making it affordable for kidney and liver cancer patients
- (b) Imatinib (Glivec) — Novartis's cancer drug. Price fell from ₹1.2 lakh/month to ₹8,000/month after compulsory licensing to Natco
- (c) Bedaquiline — J&J's TB drug. Compulsory licence granted to generic manufacturers to produce affordable versions for MDR-TB patients
- (d) Erlotinib (Tarceva) — Roche's lung cancer drug. Compulsory licence granted to Cipla in 2012
India's FIRST compulsory licence was granted in March 2012 by the Controller General of Patents to Natco Pharma for Sorafenib (brand: Nexavar), Bayer's drug for kidney cell carcinoma (kidney cancer) and hepatocellular carcinoma (liver cancer). The price drop was dramatic: Bayer's price was ~₹2.8 lakh per month; Natco's price was ₹8,880 per month — a reduction of over 96%. The grounds: Bayer's drug was not reasonably affordable, was not manufactured in India, and did not meet the reasonable requirements of the public. This case was a landmark application of Section 84 of the Patents Act. Important clarification on the other options: Glivec (Imatinib) did NOT receive a CL — its generic version (Natco) was available because Novartis's patent was rejected entirely (Section 3d). Bedaquiline also did NOT receive a CL — its patent simply expired. Erlotinib also was not CL'd — Cipla produced the generic after winning litigation on other grounds.
Q4. The "Pre-Grant Opposition" mechanism in India's patent system is significant in the context of evergreening because:
- (a) It allows patent holders to extend their patents by filing pre-grant modifications before the original patent expires
- (b) It requires all pharmaceutical companies to mandatorily disclose their drug pricing before obtaining a patent
- (c) It grants the government automatic authority to reject any secondary patent application for pharmaceutical products
- (d) It allows any person — including patient groups, civil society organisations, and generic manufacturers — to challenge a patent application on grounds including Section 3(d) before the patent is granted, preventing evergreening at source
Section 25(1) of the Indian Patents Act provides for Pre-Grant Opposition (PGO) — a mechanism allowing any person to oppose a patent application BEFORE the patent is granted. Grounds include: lack of novelty, obviousness, Section 3(d) failures, anticipation by prior art, and insufficient disclosure. This is a powerful tool against evergreening because it stops the problem at the source — before a problematic patent is granted. The Lenacapavir case (2024) is the perfect contemporary example: Sankalp Rehabilitation Trust filed PGOs challenging Gilead's salt-form patents for lenacapavir. Argentina's 2025 rejection of a similar application demonstrates how pre-grant challenges can prevent evergreening globally. Post-Grant Opposition (Section 25(2)) allows similar challenges within 12 months of patent grant — providing a second line of defence. This two-tier system of pre- and post-grant opposition is considered among the best in the world for protecting public health from evergreening.
Q5. The Gilead Sciences lenacapavir HIV drug controversy in India (2024) demonstrates which of the following?
1. Civil society Pre-Grant Oppositions can compel pharmaceutical companies to offer voluntary licences.
2. Salt forms of existing compounds are automatically patentable under TRIPS without needing to demonstrate enhanced efficacy.
3. Lenacapavir was included in India's compulsory licensing list under Section 84 of the Patents Act.
4. India's anti-evergreening framework remains relevant even for breakthrough drugs that could end epidemic diseases.
1. Civil society Pre-Grant Oppositions can compel pharmaceutical companies to offer voluntary licences.
2. Salt forms of existing compounds are automatically patentable under TRIPS without needing to demonstrate enhanced efficacy.
3. Lenacapavir was included in India's compulsory licensing list under Section 84 of the Patents Act.
4. India's anti-evergreening framework remains relevant even for breakthrough drugs that could end epidemic diseases.
- (a) 1 and 2 only
- (b) 2 and 3 only
- (c) 1 and 4 only
- (d) 1, 3 and 4
Statements 1 and 4 are correct; Statements 2 and 3 are wrong. Statement 1 CORRECT: Gilead's October 2024 voluntary licensing announcement (for 120 LMICs including India) came in the context of ongoing Pre-Grant Oppositions filed by patient groups like Sankalp Rehabilitation Trust. While causation cannot be definitively established, most analysts interpreted the VL as partly responsive to patent challenge pressure — demonstrating that PGOs can influence corporate behaviour. Statement 2 WRONG: Salt forms are NOT automatically patentable under TRIPS. India's Section 3(d) specifically requires that salt forms (new forms of known substances) must show enhanced therapeutic efficacy to be patentable. This is precisely what the lenacapavir patent opponents argue — the choline and sodium salt forms of lenacapavir don't show enhanced efficacy over the known compound. Statement 3 WRONG: There was NO compulsory licence for lenacapavir. The CL mechanism (Section 84) was NOT invoked — the patent challenge was through Pre-Grant Opposition. Statement 4 CORRECT: Even for lenacapavir — a drug showing nearly 100% HIV prevention efficacy — India's anti-evergreening framework was applied to ensure affordability. This confirms the universal relevance of the framework.
⚡ Quick Revision — Evergreening Summary
| Topic | Key Facts to Remember |
|---|---|
| Definition | Strategy to extend patent monopoly beyond 20 years by filing secondary patents on minor modifications of existing drugs (new salt, new dosage, new delivery, new combination) without genuine therapeutic improvement. Also called "secondary patenting." |
| Why Harmful | Blocks generic entry. Keeps drug prices artificially high. When patent expires, generic price drops 80–90%. Evergreening prevents this. Millions in developing countries die from unaffordable drugs. India (pharmacy of the world — 20% of global generics) is specially affected. |
| Section 3(d) | Patents Act 1970 (amended 2005). New forms of known substances (salts, polymorphs, dosages, metabolites) NOT patentable UNLESS they show significantly enhanced therapeutic EFFICACY. Key word: EFFICACY — not just bioavailability. Upheld by SC in Novartis 2013. |
| Section 3(e) | Mixtures of known compounds not patentable unless there is a SYNERGISTIC effect. Prevents combination drug evergreening. |
| Section 3(i) | Methods of treatment NOT patentable. Prevents method patent evergreening. |
| Section 84 (CL) | Compulsory Licensing. Government can authorise generic production if drug is unaffordable, unavailable, or not manufactured in India. First CL: Natco-Bayer 2012, Sorafenib (Nexavar cancer drug) — ₹2.8 lakh → ₹8,880/month. |
| Section 25 (Opposition) | Pre-Grant Opposition: anyone can challenge patent application before grant on Section 3(d) grounds. Post-Grant Opposition: challenge within 12 months of grant. Key tool against evergreening — used in Lenacapavir (2024) case. |
| Novartis v India 2013 | SC rejected Glivec (imatinib mesylate) patent. Reasoning: 30% better bioavailability ≠ enhanced therapeutic efficacy. Section 3(d) upheld. TRIPS-compliant. Glivec: ₹1.2 lakh/month (Novartis) → ₹8,000/month (Natco generic). 16,000 patients got free treatment from Natco. |
| Bedaquiline Case 2023 | J&J's attempt to extend monopoly on MDR-TB drug beyond July 2023 REJECTED by Indian Patent Office. Generic manufacturers (Lupin, Macleods) can now produce. Critical for MDR-TB treatment globally. India leads global TB burden. |
| Lenacapavir 2024 | Gilead Sciences sought patents on salt forms of HIV drug lenacapavir (100% efficacy; $42,250/year). Sankalp Rehabilitation Trust filed Pre-Grant Oppositions. Sep 2024: IPO scheduled hearings. Oct 2024: Gilead offered voluntary licences to 120 LMICs. Argentina 2025: similar patent rejected. India: decision pending. |
| Doha Declaration 2001 | WTO declaration confirming developing countries' right to use CL and TRIPS flexibilities for public health. India co-led. Foundation for India's pharma patent policy. Section 31, TRIPS + Doha = legal basis for CL. |
🚨 5 UPSC Traps — Evergreening:
Trap 1 — "Novartis won its case and got the Glivec patent in India" → WRONG! Novartis LOST. The Supreme Court of India upheld Section 3(d) and REJECTED Novartis's patent application for Glivec in April 2013 (2-0 verdict). This is one of the most important Indian judicial decisions in IP law — the fact that a global pharma giant lost to India's public health provisions is the key takeaway. Never say "Novartis won" or "the patent was granted."
Trap 2 — "Section 3(d) requires showing improved bioavailability to get a patent" → WRONG! Section 3(d) requires showing significantly enhanced THERAPEUTIC EFFICACY — not just bioavailability, not just better absorption, not just better stability. Novartis showed 30% better bioavailability for Glivec — but the SC said that was NOT enough. Bioavailability (how well the body absorbs the drug) is different from therapeutic efficacy (how well the drug actually treats the disease). The distinction is critical and has been directly tested in UPSC.
Trap 3 — "Compulsory Licensing (CL) is the same as patent rejection" → WRONG! CL and patent rejection are completely different tools. Patent rejection means the patent was never granted (Novartis-Glivec, J&J-Bedaquiline). Compulsory Licensing means the patent IS valid and in force, but the government allows a third party to use it for public benefit without the patent holder's consent (Natco-Bayer, sorafenib/Nexavar 2012). These are different legal situations with different outcomes.
Trap 4 — "India's Section 3(d) violates its TRIPS obligations" → WRONG! The Supreme Court in Novartis v. India 2013 explicitly held that Section 3(d) is TRIPS-compliant. TRIPS Article 27 requires inventions to be "new" and involve an "inventive step." Minor modifications without efficacy improvement do not constitute an inventive step — so rejecting such patents does not violate TRIPS. WIPO itself has cited India's approach as a model. Several countries have adopted similar provisions. This is UPSC-tested directly.
Trap 5 — "Lenacapavir received a Compulsory Licence in India in 2024" → WRONG! As of 2025, no CL was granted for lenacapavir in India. The challenge was through Pre-Grant Opposition (Section 25(1)) — Sankalp Rehabilitation Trust filed PGOs challenging Gilead's salt-form patent applications. Gilead then offered voluntary licences (a different mechanism — not legally mandated). The IPO hearings were scheduled in September 2024 and a decision is pending. Do not confuse CL (Section 84), Pre-Grant Opposition (Section 25(1)), and Voluntary Licences — three entirely different mechanisms.
Trap 1 — "Novartis won its case and got the Glivec patent in India" → WRONG! Novartis LOST. The Supreme Court of India upheld Section 3(d) and REJECTED Novartis's patent application for Glivec in April 2013 (2-0 verdict). This is one of the most important Indian judicial decisions in IP law — the fact that a global pharma giant lost to India's public health provisions is the key takeaway. Never say "Novartis won" or "the patent was granted."
Trap 2 — "Section 3(d) requires showing improved bioavailability to get a patent" → WRONG! Section 3(d) requires showing significantly enhanced THERAPEUTIC EFFICACY — not just bioavailability, not just better absorption, not just better stability. Novartis showed 30% better bioavailability for Glivec — but the SC said that was NOT enough. Bioavailability (how well the body absorbs the drug) is different from therapeutic efficacy (how well the drug actually treats the disease). The distinction is critical and has been directly tested in UPSC.
Trap 3 — "Compulsory Licensing (CL) is the same as patent rejection" → WRONG! CL and patent rejection are completely different tools. Patent rejection means the patent was never granted (Novartis-Glivec, J&J-Bedaquiline). Compulsory Licensing means the patent IS valid and in force, but the government allows a third party to use it for public benefit without the patent holder's consent (Natco-Bayer, sorafenib/Nexavar 2012). These are different legal situations with different outcomes.
Trap 4 — "India's Section 3(d) violates its TRIPS obligations" → WRONG! The Supreme Court in Novartis v. India 2013 explicitly held that Section 3(d) is TRIPS-compliant. TRIPS Article 27 requires inventions to be "new" and involve an "inventive step." Minor modifications without efficacy improvement do not constitute an inventive step — so rejecting such patents does not violate TRIPS. WIPO itself has cited India's approach as a model. Several countries have adopted similar provisions. This is UPSC-tested directly.
Trap 5 — "Lenacapavir received a Compulsory Licence in India in 2024" → WRONG! As of 2025, no CL was granted for lenacapavir in India. The challenge was through Pre-Grant Opposition (Section 25(1)) — Sankalp Rehabilitation Trust filed PGOs challenging Gilead's salt-form patent applications. Gilead then offered voluntary licences (a different mechanism — not legally mandated). The IPO hearings were scheduled in September 2024 and a decision is pending. Do not confuse CL (Section 84), Pre-Grant Opposition (Section 25(1)), and Voluntary Licences — three entirely different mechanisms.
